Background: As people with cystic fibrosis (PWCF) live longer due to the breakthrough drug elexacaftor-tezacaftor-ivacaftor (ETI), they have questioned whether other CF therapies could be safely discontinued. SIMPLIFY was the first prospective, randomized trial to evaluate non-inferiority of discontinuing versus continuing two therapies. The QUEST (Qualitative Understanding of Experiences in the SIMPLIFY Trial) study was conducted to understand experiences of PWCF enrolled in SIMPLIFY, including why they joined, perceptions of randomization, decision-making around study withdrawal, and considerations for future discontinuation studies.
View Article and Find Full Text PDFPLOS Glob Public Health
November 2024
Electronic nicotine delivery systems (ENDS), such as e-cigarettes, have become increasingly used across the world. To respond to global public health challenges associated with vaping, governments have implemented numerous ENDS policies. This research highlights the patterns, clustering, and transitions in U.
View Article and Find Full Text PDFJ Res Adolesc
December 2024
John Schulenberg has had significant impact on developmental science. His conceptual writing and empirical research, grounded in developmental contextualism, emphasized the critical role that developmental transitions play in shaping health risks, especially substance use, across the life course. Schulenberg's integration of developmental concepts with large-scale epidemiological studies, particularly through his leadership in the Monitoring the Future study, provides key insights into how significant life changes-such as school transitions, employment, and relationships-interact to influence well-being across adolescence and early adulthood.
View Article and Find Full Text PDF